Invacare Corp. (IVC) Trading Down 2.2%
Invacare Corp. (NYSE:IVC) shares were down 2.2% during mid-day trading on Monday . The stock traded as low as $12.14 and last traded at $12.17, with a volume of 146,752 shares. The stock had previously closed at $12.45.
Separately, Zacks Investment Research cut Invacare Corp. from a “hold” rating to a “sell” rating in a research note on Friday, April 29th.
The firm’s 50-day moving average is $12.38 and its 200 day moving average is $12.45. The company’s market capitalization is $393.85 million.
Invacare Corp. (NYSE:IVC) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.09. During the same quarter last year, the business posted ($0.23) EPS. The business earned $275 million during the quarter, compared to the consensus estimate of $270.10 million. Invacare Corp.’s revenue for the quarter was down 3.9% compared to the same quarter last year. On average, equities analysts predict that Invacare Corp. will post ($0.95) EPS for the current year.
An institutional investor recently raised its position in Invacare Corp. stock. Ancora Advisors LLC increased its stake in Invacare Corp. (NYSE:IVC) by 1.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 72,542 shares of the company’s stock after buying an additional 742 shares during the period. Ancora Advisors LLC owned approximately 0.22% of Invacare Corp. worth $1,216,000 at the end of the most recent quarter.
Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The Company’s geographical segments are Europe; North America, which includes North America/Home Medical Equipment (North America/HME) and Institutional Products Group (IPG) segments, and Asia/Pacific.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.